首页 | 本学科首页   官方微博 | 高级检索  
检索        

糖尿病视网膜病变治疗药物的开发进展
引用本文:谢瑞满.糖尿病视网膜病变治疗药物的开发进展[J].世界临床药物,2008,29(11):661-665.
作者姓名:谢瑞满
作者单位:复旦大学附属中山医院老年科、神经科
摘    要:糖尿病视网膜病变(DR)是糖尿病最常见和最严重的微血管并发症之一,其基本病理改变是血.视网膜屏障破坏及新生血管形成.目前DR的防治由以往的控制危险因素、单一提高胰岛素的降糖作用等简单原则,发展到调节葡萄糖代谢、增加胰岛素受体敏感性、抑制胰岛素抵抗及糖基化终末产物的形成、减少氧化应激等多方面.本文综述血糖控制、特殊治疗药物和中医药早期防治等用于DR内科治疗的药物的开发进展.

关 键 词:糖尿病视网膜病变  血管内皮生长因子  色素上皮衍生因子  临床治疗

Internal medicine treatment of diabetic retinopathy
XIE Rui-Man.Internal medicine treatment of diabetic retinopathy[J].WORLD CLINICAL DRUGS,2008,29(11):661-665.
Authors:XIE Rui-Man
Institution:XIE Rui-Man(Department of Gerontology , Neurology,Zhongshan Hospital,Fudan University,Shanghai 200032,China)
Abstract:Diabetic retinopathy(DR) is one of the most common and severe microangium complications of diabetes mel-litus, the fundamental pathological characteristic of which is breakdown of the blood-retinal barrier and neovascularization.In the later stage of DR, the shrinkage of the neovascular membrane, which may tractates the retina and produce detachment of the retina, results in progressive deterioration of vision.Retinal neovascularization results from both increasing of vascular stimulating factor such as vas...
Keywords:diabetic retinopathy  vascular endothelial growth factor  pigment epithelium-derived factor  drug treatment  
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号